“I look forward to meeting at TVT 2014 all those who want to learn more about our 3rd-generation Trinity technology, which we believe will be a game-changer for TAVI.” Dr. Wolfgang Goetz, CEO (+49) 170 6309920, wolfgang.goetz@transcatheter-technologies.com

REGENSBURG, Germany, — Transcatheter Technologies GmbH, an emerging medical device company that is developing a third-generation transcatheter aortic valve implantation (TAVI) system—Trinity (Click here for video) — announced today announced today the closing of the second tranche of a Series B financing. The company’s founder and CEO, Wolfgang Goetz, M.D., Ph.D., will be looking to meet with additional investors, including potential corporate partners, at the Cardiovascular Research Foundation’s “TVT 2014” meeting in Vancouver starting later this week.

The company has previously announced successful 6-month follow-up results for a pilot study of its Trinity TAVI system that is designed to be the world’s first ‘truly repositionable’ and, therefore, best TAVI system.

“The six-month clinical results are striking,” said principal investigator Prof. Dr. Christian Hengstenberg. A cardiologist at the German Heart Center, Munich, Germany, Prof. Dr. Hengstenberg. “Unlike the second-generation TAVI systems, the Trinity aortic valve is able to be positioned precisely or in fact repositioned, even after full implantation, in a safe manner. In our study, Trinity’s novel sealing cuff continues to provide outstanding results without PVL, which is an unacceptably frequent complication of TAVI⁽¹⁾. Equally important, the risk of atrioventricular (AV) block has been mitigated due to the supra-annular positioning of the Trinity valve.”

“A severe limitation of currently marketed TAVI systems is that they cannot be repositioned once fully implanted. On the other hand, Trinity is designed to solve this life-threatening issue and thereby potentially reduces the unwanted consequences of PVL and AV block,” said Wolfgang Goetz, M.D., Ph.D., CEO, a cardiac surgeon by training. “Once our Trinity valve is completely expanded and anchored above the annulus, a cardiologist can then fully assess the valve’s function to determine whether it needs to be repositioned, retrieved, or kept in the same position. This feature is absolutely unique to Trinity, which is why we have positioned Trinity as a Third-Generation TAVI System. I will be attending the ‘TVT 2014’ meeting, and I look forward to meeting with those who are interested in learning more about Trinity,” said Dr. Goetz.

⁽¹⁾ J Am Coll Cardiol. 2013 Mar 19;61(11):1125-36. doi: 10.1016/j.jacc.2012.08.1039. Epub 2013 Jan 30. Paravalvular leak after transcatheter aortic valve replacement: the new Achilles' heel? A comprehensive review of the literature. Généreux P, Head SJ, Hahn R, Daneault B, Kodali S, Williams MR, van Mieghem NM, Alu MC, Serruys PW, Kappetein AP, Leon MB.

Source: Transcatheter Technologies